Oncology

Research presented at the 2017 annual meeting of the American Society of Clinical Oncology shows childhood cancer survivors diagnosed in more recent years can expect to experience fewer serious chronic conditions than those diagnosed in earlier decades.

The doxorubicin conjugate aldoxorubicin could be a suitable alternative to standard therapies for patients with relapsed or refractory soft tissue sarcoma, say researchers.

Patients with residual invasive disease after standard neoadjuvant chemotherapy for HER2-negative breast cancer benefit from adjuvant treatment with capecitabine, CREATE-X trial data show.

Patients with prostate cancer can be classified into luminal- and basal-like subtypes using the well-known PAM50 algorithm, and the subtypes correlate with clinical outcome, researchers report.

Study findings suggest that bosutinib could be considered as an alternative to imatinib for first-line tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase.

The ARCHER 1050 investigators believe that their results establish dacomitinib as an addition to the first-line EGFR mutation-positive non-small-cell lung cancer treatment armamentarium, but caution that the associated toxicity needs to be managed.